Should Palliative Care Start Now or Wait, in Advanced Parkinson's Disease
A man with worsening Parkinson's disease is nowhere near end of life by any conventional marker, and his neurologist has to decide whether the randomized evidence for early palliative-care integration in this exact disease applies to a patient this far from what palliative care has traditionally meant.
F.D. has spent every summer for thirty years volunteering as a fishing guide for a veterans' organization, a role that has become harder each season as his Parkinson's disease has progressed to daily motor fluctuations — unpredictable off-periods where his medication simply stops working for stretches of an hour or more — alongside non-motor symptoms his neurologist has started taking as seriously as the tremor: sleep fragmentation, anxiety, and a caregiver burden his wife has begun describing openly as exhausting. Nothing about his disease trajectory today suggests he is approaching end of life; he is eight to ten years from where his neurologist expects real decline in independence, by her own clinical estimate.
That gap between his current status and any traditional sense of "palliative" is exactly what the pivotal trial on this question was designed to test. Kluger and colleagues' 2020 randomized controlled trial in JAMA Neurology assigned patients with Parkinson's disease and related disorders, not selected for advanced or terminal illness, to either standard neurology care alone or standard care plus outpatient palliative care integrated from early in the disease course. The palliative-care group showed significantly better quality of life at six months, the trial's primary time point, measured well before the disease reached any conventional end-of-life stage, along with lower non-motor symptom burden and better motor symptom severity. Caregiver burden is where the result turns awkward for the argument it usually gets recruited into: it was a co-primary outcome, and at six months it did not differ significantly between the groups. It favored palliative care only at twelve. The tension isn't whether integration helps — the randomized result says it does — but whether every patient with F.D.'s disease burden should get it now, given genuinely limited staffing capacity.
F.D. himself raised none of this unprompted — when his neurologist asked how the season had gone, he talked about the fishing trips he'd had to hand off to a co-guide twice this summer, not about his own sleep or mood, a pattern she has come to recognize after years of seeing him: he narrates his disease through what it has taken from his role with other people long before he'll describe what it's doing to him directly. So the two things she is most confident about sit in different evidentiary categories, and she knows it: the quality-of-life benefit she can point to a randomized six-month result for, and the caregiver benefit she cannot — for that one she has a null co-primary at six months, a separation at twelve, and his wife's own account, which is the least generalizable and the most specific piece of evidence in front of her.
In the movement disorders clinic, between his medication checks
I want to refer him to outpatient palliative care now, not once his disease looks more advanced. The Kluger trial randomized patients like him — not selected for terminal illness, just real Parkinson's disease burden — to early integrated palliative care versus standard neurology care alone, and found significantly better quality of life and lower non-motor symptom burden at six months. I'll be accurate about the caregiver half rather than overclaim it, because it's the part of his picture I care most about: caregiver burden was a co-primary outcome and it came back null at six months. It only separated at twelve. So what I can honestly say about his wife is that the trial supports a benefit that takes a year to show up, not one that arrives by his next visit — which is an argument for starting now, not for waiting.
I don't disagree with the evidence, but I want to name the real capacity problem honestly rather than pretend it away — our program's outpatient slots are limited, and they're currently allocated heavily toward patients with advanced or terminal-phase disease. If we start referring every Parkinson's patient at F.D.'s stage based on this trial, we risk running out of capacity for patients whose need is more acute right now, and the trial itself doesn't tell us how to make that tradeoff.
That's a real, unresolved staffing question, and I don't think it has a clean pharmacologic answer. What I'd add from the medication side is that his caregiver burden and non-motor symptoms may also reflect undertreated motor fluctuation itself — his off-periods running two to three hours daily suggests his current levodopa schedule may benefit from adjunct therapy or dose-timing changes before we conclude palliative-care referral is the primary lever here. I'd pursue both: optimize his motor regimen now, and support the neurologist's referral as a genuine priority case within whatever capacity your program has, rather than treating this as an all-or-nothing policy decision for every patient at his stage.
Agreed: referral placed to outpatient palliative care, prioritized given his wife's documented caregiver exhaustion, alongside a levodopa dose-interval adjustment to address his motor fluctuations directly rather than treating the palliative referral as the sole intervention.
Not agreed, and named explicitly as an open policy question rather than resolved for this visit alone: whether every Parkinson's patient at F.D.'s disease stage should be routinely referred this early, given genuinely limited program capacity. The Palliative Care Physician wants a program-level conversation about triage criteria before this becomes an informal new referral pattern; the Movement Disorders Neurologist believes the trial evidence is strong enough that the program's capacity, not the referral threshold, is what should change.